[go: up one dir, main page]

BRPI0408491A - tratamento da doença de alzheimer - Google Patents

tratamento da doença de alzheimer

Info

Publication number
BRPI0408491A
BRPI0408491A BRPI0408491-8A BRPI0408491A BRPI0408491A BR PI0408491 A BRPI0408491 A BR PI0408491A BR PI0408491 A BRPI0408491 A BR PI0408491A BR PI0408491 A BRPI0408491 A BR PI0408491A
Authority
BR
Brazil
Prior art keywords
disease
alzheimer
ifn
treat
treatment
Prior art date
Application number
BRPI0408491-8A
Other languages
English (en)
Inventor
Luigi Grimaldi
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of BRPI0408491A publication Critical patent/BRPI0408491A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"TRATAMENTO DA DOENçA DE ALZHEIMER". A invenção se refere à aplicação de interferon-<225> (IFN-<255>) para tratar e/ou prevenir a doença de Alzheimer (AD), a doença de Creutzfeid-Jakob (CJD) ou a do.ença de Gerstmann-Strãussier-Scheinker (GSSD). Adicionalmente se refere à aplicação de IFN-<255> em combinação com um agente para tratar a doença de Alzheimer para tratar e/ou prevenir a doença de Alzheimer. é preferencial a aplicação de IFN-<255> em combinação com um inibidor da colinesterase para tratar e/ou prevenir a doença de Alzheimer de início precoce.
BRPI0408491-8A 2003-03-19 2004-03-17 tratamento da doença de alzheimer BRPI0408491A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03100716 2003-03-19
PCT/EP2004/050316 WO2004082706A2 (en) 2003-03-19 2004-03-17 Ifn-beta alone or in combination with other medicaments for treating alzheimer's disease and demens disorders

Publications (1)

Publication Number Publication Date
BRPI0408491A true BRPI0408491A (pt) 2006-04-04

Family

ID=33016977

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408491-8A BRPI0408491A (pt) 2003-03-19 2004-03-17 tratamento da doença de alzheimer

Country Status (14)

Country Link
US (1) US20070110715A1 (pt)
EP (1) EP1620124A2 (pt)
JP (1) JP2006520368A (pt)
KR (1) KR20050115279A (pt)
CN (1) CN1791423A (pt)
AR (1) AR043660A1 (pt)
AU (1) AU2004222529A1 (pt)
BR (1) BRPI0408491A (pt)
CA (1) CA2516990A1 (pt)
EA (1) EA009668B1 (pt)
IL (1) IL170751A0 (pt)
MX (1) MXPA05009986A (pt)
NO (1) NO20054744L (pt)
WO (1) WO2004082706A2 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2562069A1 (en) * 2004-04-14 2005-10-27 Warner-Lambert Company Llc Therapeutic combination for treatment of alzheimers disease
US7695911B2 (en) 2005-10-26 2010-04-13 Celera Corporation Genetic polymorphisms associated with Alzheimer's Disease, methods of detection and uses thereof
EP2001463B1 (en) * 2006-03-20 2013-07-03 Council of Scientific and Industrial Research A pharmaceutical composition useful as acetyl cholinesterase inhibitors
CN101116670B (zh) * 2006-08-01 2010-11-10 广州和竺生物科技有限公司 可提供活性甲基或参与甲基转移的化合物作为制备治疗病毒性疾病的药的应用
CN101516401A (zh) * 2006-08-21 2009-08-26 诺瓦提斯公司 阿尔茨海默病进展的生物标记
TWI432195B (zh) * 2007-10-03 2014-04-01 Kowa Co 神經細胞死亡抑制劑
EP2364150A1 (en) * 2008-11-11 2011-09-14 Targacept Inc. Treatment with alpha 7-selective ligands
US20110081428A1 (en) * 2009-09-16 2011-04-07 The Buck Institute For Age Research Use of thioflavin-like compounds to increase life span and/or health span
US9295669B2 (en) 2010-12-14 2016-03-29 Hoffman La-Roche Inc. Combination therapy for proliferative disorders
CN102382096A (zh) * 2011-09-06 2012-03-21 清华大学 异香豆素及其衍生物的制备方法
CN102707065A (zh) * 2012-03-23 2012-10-03 常熟市虞山绿茶有限公司 Prohibitin蛋白抗体在制备诊断老年性痴呆的试剂盒中的应用
UA107653U (uk) 2012-10-01 2016-06-24 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів
US9116974B2 (en) * 2013-03-15 2015-08-25 Robert Bosch Gmbh System and method for clustering data in input and output spaces
CN106754995B (zh) * 2016-11-25 2020-07-10 山东农业大学 中华蜜蜂AccCDK5基因及AccCDK5r1基因及其应用
RU2729391C2 (ru) * 2018-12-28 2020-08-06 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Моноклональное антитело, способное нейтрализовать биологическую активность интерферона бета-1а человека
CN109518211B (zh) * 2019-01-08 2020-11-06 合肥工业大学 一种芳香偶酰类化合物的电化学合成方法
WO2020144753A1 (ja) * 2019-01-09 2020-07-16 公立大学法人大阪 神経変性疾患の予防又は治療薬
WO2021090172A1 (en) * 2019-11-04 2021-05-14 Ck Biotechnology Co. Compositions and methods for suppressing and/or treating neurodegenerative diseases and/or a clinical condition thereof
WO2023080687A1 (ko) * 2021-11-03 2023-05-11 가천대학교 산학협력단 아밀로이드 베타 멀티머 저해 약물의 고속 대량 스크리닝 방법 및 독소루비신 또는 이의 유도체를 포함하는 아밀로이드 베타의 올리고머화 또는 섬유화 억제용 조성물
KR102767287B1 (ko) * 2021-11-03 2025-02-13 가천대학교 산학협력단 독소루비신 또는 이의 유도체를 포함하는 아밀로이드 베타의 올리고머화 또는 섬유화 억제용 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000057879A1 (en) * 1999-03-26 2000-10-05 Barry Reisberg Treatment of brain changes with myelin protective agents
AU783208B2 (en) * 1999-12-09 2005-10-06 Novartis Vaccines And Diagnostics, Inc. Method for administering a cytokine to the central nervous system and the lymphatic system

Also Published As

Publication number Publication date
WO2004082706A2 (en) 2004-09-30
AU2004222529A1 (en) 2004-09-30
CA2516990A1 (en) 2004-09-30
CN1791423A (zh) 2006-06-21
JP2006520368A (ja) 2006-09-07
US20070110715A1 (en) 2007-05-17
IL170751A0 (en) 2011-08-01
EA200501479A1 (ru) 2006-02-24
WO2004082706A3 (en) 2005-01-13
EP1620124A2 (en) 2006-02-01
MXPA05009986A (es) 2005-11-04
AR043660A1 (es) 2005-08-03
KR20050115279A (ko) 2005-12-07
NO20054744L (no) 2005-10-14
EA009668B1 (ru) 2008-02-28

Similar Documents

Publication Publication Date Title
BRPI0408491A (pt) tratamento da doença de alzheimer
GB0223040D0 (en) Therapeutic compounds
EE04221B1 (et) Östrogeeni kasutamine ravimi valmistamiseks füüsiliste seisundite raviks menopausijärgsetel isikutel
GB0108592D0 (en) Therapeutic agents
BR0307522A (pt) Utilização de um inibidor de lipoxigenase-15 para a manufatura de um medicamento, métodos para tratamento e prevenção e kit para o diagnóstico de predisposição à perda óssea
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
BR9814923A (pt) Método para tratamento de doença de alzheimer
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
BR0206639A (pt) Combinações de inibidor(es) da absorção do esterol com modificador(es) do sangue para o tratamento de condições vasculares
BR0117009A (pt) Composiçoes para utilização no tratamento de distúrbios associados a ige
BR0111601A (pt) Método para o tratamento de doença cardiovascular
MA29787B1 (fr) Traitement de maladies auto-immunes
CY1119190T1 (el) Χρηση αναστολεων της il-18 για αγωγη ή προληψη βλαβων του κνς
BRPI0408268A (pt) moléculas e métodos de prevenção ou inibição da atividade da malária in vivo e de tratamento de pessoas
BR0201524A (pt) Tratamento de combinação para ansiedade e depressão
BR0313081A (pt) Combinação de um inibidor de aromatase com um bisfosfanato
MXPA03006776A (es) Uso de inhibidores de interleucina-18 para el tratamiento y/o prevencion de enfermedad cardiaca.
TR200200278T2 (tr) Kalsilitik bileşimler
PT1133296E (pt) Nova aplicacao terapeutica da nicergolina
BRPI0607684A2 (pt) composição farmacêutica, método para prevenir ou tratar distúrbios de depressão ou ansiedade, e, uso de (s)-n-[2-(1,6,7,8-tetraidro-2h-indeno[5,4-b]furan-8-il)-eti l]-propionamida
BR0015121A (pt) Composição farmacêutica utilizável para o tratamento de inflamação em humanos, e, método de tratamento de inflamação
PL367707A1 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
PT1401455E (pt) Utilizacao de um adsorvente de fosfato para combater doencas vasculares
NO20012849D0 (no) Ny terapeutisk anvendelse for hepariner med lav molekylvekt
DK1235573T3 (da) Kombination af riluzol og gabapentin og anvendelse deraf som medikament ved behandling af motorneuronsygdomme

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.